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Intravesical instillation of bacillus Calmette Guérin (BCG) 
has been the therapy of choice for the treatment of high-
risk non-muscle-invasive bladder cancer (NMIBC) for 
several decades, increasing considerably the survival of 
these patients. For papillary tumours, the instillations 
are applied as adjuvant after trans-urethral resection of 
the bladder (TURB); however, carcinoma in situ (CIS) 
cannot be excised and, in this case, BCG is used without 
prior surgery. Despite the advantages provided by this 
treatment, with around 70% of patients relapse-free after 
5 years, remarkable improvements in the outcome of this 
therapy have not been achieved since the introduction 
of maintenance instillation cycles (1). This is probably 
related to two important facts: (I) administration of BCG 
varies among different hospitals, including bacterial strain, 
concentration and schedule; (II) the exact mechanism of 
action of BCG in the elimination of bladder cancer is not 
completely understood.
To address the first of these issues, clinical trials have 
been designed to compare treatment routines. Although 
these clinical trials have been rather scarce and, in many 
occasions difficult to compare, it seems clear that the most 
successful regime includes an induction phase of 6 weekly 
instillations followed by a maintenance cycle which varies 
in length and calendar, but in general consists of 2 or 
3 weekly instillations alternating with rest periods (1). A 
second group of clinical trials aimed to evaluate the effect 
of different BCG strains in the elimination of bladder 
cancer. However, disappointingly, different trial setups and 
contradictory results do not allow a definitive conclusion 
on whether the use of different strains strongly affects the 
efficacy of the BCG treatment (1).
On the other hand, extensive laboratory-based 
research over the years has tried to unveil the molecular 
mechanisms of BCG against cancer and so develop novel 
strategies to improve this therapy. These research efforts 
have included studies on the interaction between BCG 
and different components of the immune system, as well 
as projects involving the generation of engineered BCG 
variants expressing either cytokines or immune-stimulating 
molecules. Further, in an attempt to improve efficacy while 
decreasing BCG adverse effects, the description of new 
bacterial-based therapies for bladder cancer is under study.
The paper by Rodriguez et al. (2) is part of the efforts 
to define new BCG strains that might improve the rate of 
success in the treatment of bladder cancer. This work has 
the general goal of triggering a more efficient immune 
response, based on the use of a recombinant BCG strain 
expressing the detoxified Pertussis toxin derivative, S1 
subunit-9K/129G (S1PT), to try and stimulate immune 
effector cells more potently. The effect of culturing the 
toxin derivative-expressing BCG in vitro with human 
peripheral blood mononuclear cells (PBMC) was studied, 
and the degree of CD4+ T lymphocyte activation, as well 
as the cytokines produced in the cultures, was evaluated. 
The authors exposed PBMC from healthy donors to 
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mycobacteria using a multiplicity of infection (MOI) of 
0.1, previously described as optimal for in vitro infection 
of macrophages, and compared the effect of wild type (wt) 
BCG with that of the engineered BCG-S1PT. Culture 
supernatants contained more cytokines when exposed to 
recombinant bacteria than when wt BCG was used, however, 
the dose did not correlate with the vaccination status of the 
donors. One striking result is that there is high variation 
in the amount of cytokines released by each donor and the 
authors suggest a personalized test for patients undergoing 
BCG treatment. The release of cytokines in bladder cancer 
patients treated with BCG can be easily analysed in urine 
and several studies have identified increased cytokine 
concentrations after instillations (3,4). In general, when 
patient urine was analysed early after instillations, 24–48 h, 
a considerable degree of acute inflammation is still ongoing 
and pro-inflammatory cytokines such as tumour necrosis 
factor (TNF)-α, IL-6, IL-1β, and IL-8 could be detected. 
Several groups have proposed the use of these soluble 
factors, alone or in combination with other clinical data, as 
biomarkers of treatment response. For example, vascular 
endothelial growth factor (VEGF) (5), IL-8 (6-8) or the 
nomogram Cytokine Panel for Response to Intravesical 
Therapy (CyPRIT) (9,10). Recently, the analysis of 
urine samples as late as one week after the contact with 
mycobacteria, has also been shown to provide information 
on the prolonged immune response taking place in the 
site of the tumor (11). Importantly, the release into urine 
of very large amounts of soluble factors like CXCL10 
(>250 pg/mL) accompanied by high levels of IL-6 and 
IL-8 (>200 and >400 pg/mL respectively), was detected in 
those patients that had to interrupt BCG therapy, e.g., due 
to discomfort, suggesting that an excessive inflammatory 
response might be detrimental for the patients’ ability 
to complete the full course of treatment. These recent 
observations might imply that devising experimental 
conditions to stimulate the highest possible immune 
response might not necessarily be optimal for patients and 
needs to be balanced with the ability of the patients to 
tolerate this therapy. More information is still needed to 
establish good soluble biomarkers in urine, nonetheless, 
recent efforts are probably closer to help establishing novel 
follow-up analyses of patients and semi-personalized tools 
for prognosis. 
The exact mechanism of action of BCG to eliminate 
bladder cancer is not completely understood. Besides the 
soluble factors found in urine of BCG-treated bladder 
cancer patients, several immune cell populations infiltrate 
the bladder after instillations (12,13). Neutrophils and 
monocytes are recruited to the bladder in large amounts 
after BCG instillations and different types of effector cells, 
mainly natural killer (NK) cells and NKT cells are involved 
in direct elimination of bladder cancer cells (14). 
Another aspect studied in the paper by Rodriguez 
et al. (2) was the degree of activation of CD4 T cells, 48 h 
after co-incubation with BCG shown by the expression of 
the activation markers CD25 and CD69. However, there 
was heterogeneity in the percentage of activated CD4+ 
T cells among different donors and this measurement 
represents only one the various immune effector cascades 
that could be involved in elimination of the tumour. In fact, 
the data from Rodriguez et al. show that CD4 stimulation 
does not correlate with cytokine production: BCG was 
more potent activating CD4+ T cells than the engineered 
mycobacteria. In contrast, as mentioned above, cytokine 
production was higher in response to the recombinant 
BCG-S1PT than to the wt BCG, thus other cel l 
populations must be contributing to the overall response 
against mycobacteria. While this type of study confirms 
that the incubation with mycobacteria and, in particular 
with engineered mycobacteria can stimulate different 
arms of the immune system, the effector cells contributing 
to the killing of bladder cells were not identified in the 
cytotoxicity assays reported in this system. Data from model 
systems using experimental animals demonstrated that 
antigen presentation is not the main mechanism for bladder 
cancer elimination in the context of BCG (15). Importantly, 
since the beginning of the use of BCG therapy against 
bladder cancer, various lines of evidence have suggested the 
involvement of the innate immune system and, in particular, 
of NK cells: initially experiments using mice, revealed 
that NK cells participate actively in the elimination of the 
tumour (16,17). Later, this idea was also demonstrated 
in vitro in many complementary research reports (14,18,19). 
A population of CD3+ lymphocytes expressing NK receptors 
has also been suggested to participate in the elimination of 
bladder cancer in the context of BCG activation of DCs by 
mediation of NK receptors.
 In all these examples, NKG2D-ligands expressed in 
tumour cells were crucial for the recognition of bladder 
cancer (20-22). Recently, an NK subset specialized in the 
recognition of tumours has been demonstrated to become 
activated after incubation with BCG in vitro (23). Thus, 
more clinical research on the role of the innate immune 
response in bladder cancer treated patients seems of crucial 
importance in order to profit from the effect of BCG 
S519Translational Andrology and Urology, Vol 8, Suppl 5 December 2019
  Transl Androl Urol 2019;8(Suppl 5):S517-S520 | http://dx.doi.org/10.21037/tau.2019.12.23© Translational Andrology and Urology. All rights reserved.
on innate immunity. Although considerable laboratory-
based research data has been produced, translation of these 
ideas into the clinic is, in general, scarce. Communication 
between basic and clinical researchers is paramount to 
confirm those hypotheses consistently generated by several 
independent non-clinical laboratories. Many efforts on 
understanding the mechanism of action of BCG against 
bladder cancer and on improving the efficacy of this 
treatment are focussed on theoretical aspects to improve 
patient response and lower BCG toxicity. In addition, 
scientists are trying to overcome worldwide episodes of 
BCG shortage due to manufacturing problems (24) at the 
same time that other studies focussing on the improvement 
of a vaccine for tuberculosis are taking place (25). Thus, 
we should all get together to achieve that bladder cancer 
patients benefit from all the research avenues with 
conclusive data, including that on more effective BCG 
preparations or on the design of non-pathogenic MTB 
strains as new therapeutic agents.
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